Cardiology has historically been a hospital-centric specialty, but the shift toward outpatient settings has accelerated meaningfully over the last 24 months, particularly in procedures that once required significant inpatient infrastructure. Recent industry data indicate that as many as one-third of all elective cardiac procedures are now expected to occur in ASCs by the middle of this decade, with key drivers including advanced device miniaturization, transradial access techniques, enhanced percutaneous interventions, and patient preference for same-day care over multi-day hospital stays.

The trend is not merely anecdotal. The American College of Cardiology launched the Cardiovascular ASC Registry Suite in early 2024 as a formal acknowledgment of the rapid acceleration of outpatient cardiac care—signaling that this migration is now critical enough to warrant robust data tracking.

From a financial perspective, the shift has major implications. Even moderating Medicare’s reimbursement differential between hospital outpatient departments (HOPDs) and ASCs would continue to favor ASCs: Medicare still reimburses identical outpatient services at roughly 2–4× higher rates in HOPDs than in ASCs, purely based on site-of-service payment policy.

Beyond the Medicare population, private insurer strategies increasingly reward lower-cost settings and bundled payments that favor ambulatory care. For high-volume cardiac cases such as electrophysiology studies, pacemaker implantation, and peripheral vascular interventions, shifting these cases to ASCs can yield tens of millions of dollars in regional healthcare savings, while preserving or even improving outcomes for appropriately selected patients.

For ASC owners the message is clear: cardiology isn’t just a growth line item—it is one of the most valuable, sustainable, and high-margin expansion strategies available in outpatient surgery today.